AI Portfolio Summary
In 2025 Q4, SR ONE CAPITAL MANAGEMENT, LP maintained a portfolio of 13 distinct positions. The most significant new addition to the portfolio was Ultragenyx Pharmaceu, which now represents 0.45% of the total fund value. They heavily accumulated shares in Zenas BioPharma, Inc, increasing their position by 2.6%. The fund also reduced its exposure to Mineralys Therapeuti by 26.0%.
Total Positions
13
Quarter
2025 Q4
Top Holding
ZBIO (25.9%)
Top 10 Concentration
97.7%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
1-13 of 13
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ZBIO
Zenas BioPharma...
|
Healthcare | 25.90% | 15.77% |
#1
2
Prev: #3
|
10.0 | 126,315 | 2.6% |
P
S
|
5,037,854 | $182,924,479 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
Arcellx, Inc.
|
Healthcare | 21.66% | 27.86% |
#2
1
Prev: #1
|
8.7 | no change | no change |
P
S
|
2,346,630 | $153,000,276 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CRSP
CRISPR Therapeu...
|
Healthcare | 15.14% | 19.11% |
#3
1
Prev: #2
|
6.1 | no change | no change |
P
S
|
2,038,763 | $106,912,732 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DSGN
Design Therapeu...
|
Healthcare | 8.67% | 7.11% |
#4
2
Prev: #6
|
3.5 | no change | no change |
P
S
|
6,526,476 | $61,218,345 | 2021 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLYS
Mineralys Thera...
|
Healthcare | 8.03% | 11.59% |
#5
1
Prev: #4
|
3.3 | -549,967 | -26.0% |
P
S
|
1,563,966 | $56,756,326 | 2023 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SPRY
ARS Pharmaceuti...
|
Healthcare | 6.62% | 5.83% |
#6
1
Prev: #7
|
2.6 | no change | no change |
P
S
|
4,012,903 | $46,750,320 | 2022 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORIC
ORIC Pharmaceut...
|
Healthcare | 5.34% | 7.84% |
#7
2
Prev: #5
|
2.1 | no change | no change |
P
S
|
4,514,929 | $37,753,841 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALMS
Alumis Inc.
|
Healthcare | 2.71% | 1.13% |
#8
1
Prev: #9
|
1.1 | no change | no change |
P
S
|
1,959,896 | $19,128,585 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ORKA
Oruka Therapeut...
|
Healthcare | 1.85% | 1.20% |
#9
1
Prev: #8
|
0.7 | no change | no change |
P
S
|
430,330 | $13,043,302 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCS
Oculis Holding ...
|
Healthcare | 1.81% | 0.82% |
#10
1
Prev: #11
|
3.0 | 318,522 | 98.8% |
P
S
|
641,022 | $12,801,209 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENGN
enGene Holdings...
|
Healthcare | 0.96% | 0.74% |
#11
1
Prev: #12
|
0.4 | no change | no change |
P
S
|
747,750 | $6,752,183 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NKTX
Nkarta, Inc.
|
Healthcare | 0.87% | 1.00% |
#12
2
Prev: #10
|
0.3 | no change | no change |
P
S
|
3,333,333 | $6,166,666 | 2022 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RARE
Ultragenyx Phar...
|
Healthcare | 0.45% | — |
#13
Prev: #—
|
2.2 | 137,753 | no change |
NEW
|
137,753 | $3,168,319 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-13 of 13 holdings